Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Working paper series (Congressional Budget Office)
- Author(s):
- Anderson-Cook, Anna, author Maeda, Jared, author Nelson, Lyle, author
- Contributor(s):
- United States. Congressional Budget Office, issuing body.
- Publication:
- [Washington, DC] : Congressional Budget Office, March 2019
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Health Expenditures -- statistics & numerical data Health Expenditures -- trends Medicaid -- economics Medicare Part D -- economics Prescription Drugs -- economics Drug Costs Economics, Pharmaceutical -- trends Forecasting Medicaid -- trends Medicare Part D -- trends Orphan Drug Production -- economics Humans United States
- Genre(s):
- Technical Report
- Abstract:
- In this working paper, the Congressional Budget Office examines the prices paid for specialty drugs and spending on those drugs in Medicare Part D and Medicaid from 2010 to 2015. Specialty drugs treat chronic, complex, or rare conditions, frequently have high prices, and may require special handling or monitoring of patients. The retail prices paid to pharmacies for brand-name specialty drugs are similar in Medicare Part D and Medicaid, but net prices are much higher in Medicare Part D because rebates from manufacturers are substantially lower than in Medicaid. In 2015, the weighted average net price for 50 top-selling brand-name specialty drugs in Medicare Part D was $3,600 per "standardized" prescription--a measure that roughly corresponds to a 30-day supply of medication--whereas the weighted average net price for the same set of drugs in Medicaid was $1,920. In Medicare Part D, net spending on specialty drugs rose from $8.7 billion in 2010 to $32.8 billion in 2015. In Medicaid, net spending on specialty drugs roughly doubled over the same period, reaching $9.9 billion in 2015. For beneficiaries in the Medicare Part D program who took brand-name specialty drugs, average annual net spending on such drugs per beneficiary (in 2015 dollars) increased from $11,330 in 2010 to $33,460 in 2015.
- Copyright:
- The National Library of Medicine believes this item to be in the public domain. (More information)
- Extent:
- 1 online resource (1 PDF file (58 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101753144 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101753144